BioSpace News Archive

Transcenta Holding Limited announces that it has received approvals from China CDE and South Korea MFDS to initiate TranStar 301 global Phase III pivotal trial of Osemitamab in combination with Nivolumab and chemotherapy for the first-line treatment of patients with HER2 negative, CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal adenocarcinoma.

Kexing Biopharmaceutical (688136.SH) has accomplished the impressive feat of being recognized on June 27 as one of “China’s Top 20 Biopharmaceutical Enterprises” (blood products, vaccines and insulin) for two consecutive years.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced late-breaking new clinical data demonstrating that KidneyIntelX in vitro prognostic use was associated with post-test actions that led to sustained improvements in both type 2 diabetes and chronic kidney disease health through 12 months.

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered direct offering for total gross proceeds of $25 million, before deducting the placement agents’ fees and other offering expenses.

As of the end of 2022, the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, offered 1,860+ Greener Alternative Products in its Life Science portfolio.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company, has secured a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co., Ltd. (“O-Bank” or the “Bank”).

National Tsing Hua University in Taiwan signed a BOT hospital contract with privately owned Kaohsiung Medical University on July 4th, with NTHU President W. John Kao and KMU Director Yi-chen Wang signing the contract.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 116,550 restricted stock units of Atara’s common stock to five newly hired employee.

Jaguar Health, Inc. announced the voting results of the Company’s 2023 Annual Meeting of Stockholders held on July 7, 2023.

Sensient Technologies Corporation will hold its conference call to discuss 2023 second quarter results at 8:30 a.m. CDT on Friday, July 21, 2023.